June 25, 2026 Teclistamab + Daratumumab/Lenalidomide Shows Deep Responses in Newly Diagnosed Multiple Myeloma: Phase 2 MajesTEC-5 Trial Insights
April 6, 2026 Isatuximab Improves MRD Negativity in Newly Diagnosed Multiple Myeloma: EMN24 IsKia Trial Results
March 24, 2026 PANGEA-SMM: A Novel Prediction Model for Smoldering Multiple Myeloma Progression Across International Cohorts
